Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Celldex Therapeutics, a wholly-owned subsidiary of Avant Immunotherapeutics, has received Federal Trade Commission approval under the Hart-Scott Rodino act, clearing Avant's proposal to award Pfizer exclusive rights to CDX-110, an investigational vaccine currently under development.
Subscribe to our email newsletter
The agreement also gives Pfizer exclusive rights to the use of this vaccine targeting the tumor specific EGFR mutant EGFRvIII in other potential indications.
On April 16, 2008, Pfizer and Celldex announced that they entered into an agreement under which Pfizer would be granted an exclusive worldwide license to CDX-110, currently being evaluated in a Phase II study for the treatment of glioblastoma multiforme.